Details of the Drug

General Information of Drug (ID: DMO1VHC)

Drug Name
ALX-0061
Synonyms Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx
Indication
Disease Entry ICD 11 Status REF
Autoimmune diabetes 5A10 Phase 2 [1]
Rheumatoid arthritis FA20 Phase 2 [2]
Systemic lupus erythematosus 4A40.0 Phase 2 [2]
Drug Type
Antibody
Cross-matching ID
TTD ID
D05NIR
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 6 receptor (IL6R) TT0E5SK IL6RA_HUMAN ; IL6RB_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Autoimmune diabetes
ICD Disease Classification 5A10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 6 receptor (IL6R) DTT IL6R; IL6ST 1.13E-04 1.32 1.28
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8363).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.